NEJM Group

NEJM Group

Book and Periodical Publishing

Waltham, MA 89,899 followers

Transforming tomorrow’s health care practice – with knowledge you need today.

About us

NEJM Group brings together the people and products that have made the New England Journal of Medicine, NEJM Journal Watch, NEJM Knowledge+, and NEJM Catalyst, leaders in providing the medical knowledge health care professionals need to deliver the best patient care. The goal of NEJM Group is to meet the rapidly growing demand for essential medical information and to disseminate that content in new ways to a broader global health care community than ever before. Our publications reach health care professionals around the globe — making connections between clinical science and clinical practice that advance medical knowledge, health care delivery, and patient outcomes. NEJM Group is a division of the Massachusetts Medical Society.

Website
http://NEJMgroup.org
Industry
Book and Periodical Publishing
Company size
201-500 employees
Headquarters
Waltham, MA
Type
Nonprofit
Founded
1812
Specialties
medical publishing, medical education, medical research, clinical research, health care, and public health

Locations

Employees at NEJM Group

Updates

  • View organization page for NEJM Group

    89,899 followers

    Anti–Interleukin-23 Autoantibodies and Severe Infections    This editorial describes the science behind a study of an autoimmune response against cytokines in persons with thymoma and severe infections.    Figure 1 from the editorial illustrates interleukins 12 and 23 and the effects of anti–interleukin-23 autoantibodies.     Interleukins 12 and 23 are produced mainly by myeloid cells on recognition of pathogen-associated molecular patterns (PAMPs) by pattern-recognition receptors (Panel A). On release, they stimulate T cells and other innate lymphoid populations such as natural killer cells and mucosal-associated invariant T cells, which then go on to produce immune-activating cytokines such as interferon-γ and interleukins 17 and 22 (Panel B). Autoantibodies against both interleukin-12 and interleukin-23 have been described, more often in patients with thymoma than in healthy persons or persons with autoimmune polyglandular syndrome type 1, but only anti–interleukin-23 autoantibodies seem to be clearly associated with opportunistic infections, whereas anti–interleukin-12 antibodies result only in a partial immune deficit (Panel C). Anti–interleukin-23 antibodies block the intracellular signaling downstream of receptors for interleukin-23, such as that mediated by signal transducer and activator of transcription 3 and 4 (STAT3 and STAT4), and block production of granulocyte–macrophage colony-stimulating factor (GM-CSF), interleukins 17 and 22, and interferon-γ (Panel D). IFN denotes interferon, IL interleukin, Th1 type 1 helper T cell, and Th17 type 17 helper T cell.    Read the science behind the study in the editorial “Anti–Interleukin-23 Autoantibodies and Severe Infections” by Mihai G. Netea, M.D., Ph.D., and Frank van de Veerdonk, M.D., Ph.D., from Radboudumc and The University of Bonn: https://nej.md/43qpgVu 

    • Interleukins 12 and 23 and the Effects of Anti–Interleukin-23 Autoantibodies
  • View organization page for NEJM Group

    89,899 followers

    “In January, a leading health care industry magazine placed me on its list of ‘10 executives to watch in 2024’ and asked how I will navigate my role in ‘the face of broad political pushback to DEI [diversity, equity, and inclusion] efforts,’” writes Aletha Maybank, MD, MPH, in a new Perspective. “My immediate reaction? Lord have mercy upon me, I’m about to be a target. Again.    “Advancing workplace DEI as hired DEI, equity, or health equity officers — whether in health systems, academia, or corporations — has always been tough, but it is especially rough right now. Not only are our long-standing efforts and those of many leaders who came before us being attacked, so are we — and directly. Since the public murder of George Floyd opened a door for speaking more directly about racism, some of us are increasingly receiving violent and abhorrent messages, even death threats at our homes. All this aggression seeks to silence us, with the larger goal of shutting this opened door forever.” Continue reading the Perspective “The Plight of DEI Leaders — Heavy Expectations and Limited Protection” by Aletha Maybank, MD, MPH, from the American Medical Association: https://nej.md/4crK2Iz

    • The latest attack comes from my own profession: a small group of physicians from within one medical specialty society proposed a resolution, that was fortunately defeated by vote, to “sunset” all DEI efforts. 
Perspective 
Aletha Maybank, M.D., M.P.H.
  • View organization page for NEJM Group

    89,899 followers

    Paroxysmal nocturnal hemoglobinuria, or PNH, is a rare disease characterized by hemolysis, thrombosis, and bone marrow failure. Intravenous anti-C5 monoclonal antibodies are the standard treatment; however, many patients remain anemic, mainly because of ongoing activation of extravascular hemolysis mediated by macrophages ingesting C3 fragment-coated red cells. Now, two phase 3 trials have evaluated the efficacy and safety of iptacopan, an oral complement factor B inhibitor, in PNH.    Research findings are summarized in a new Quick Take video. https://lnkd.in/eZAWEA46    Read the related Original Article by Régis Peffault de Latour, M.D., et al.: https://nej.md/48QKlcU    #ClinicalTrials #MedicalResearch 

  • View organization page for NEJM Group

    89,899 followers

    The April 2024 special theme issue of NEJM Catalyst Innovations in Care Delivery, guest edited by Amy Compton-Phillips, MD, includes an in-depth look at the use of immersive technologies to enhance clinical care delivery and support clinical staff at the U.S. Department of Veterans Affairs.    📌 Read the article: https://nej.md/491xCnx    Here are more highlights from the April issue:      𝗖𝗔𝗦𝗘 𝗦𝗧𝗨𝗗𝗜𝗘𝗦  🏥 A Dynamic Clinical Decision Support Tool to Improve Primary Care Outcomes in a High-Volume, Low-Resource Setting https://nej.md/48XtIMt    💊 Duke Health Integrated Pain and Wellness Program — A Proactive Population Health Model https://nej.md/4amvMPw    📈 Remote Patient Monitoring to Transform Management of Febrile Neutropenia in Cancer Patients https://nej.md/3vpMbUb    𝗔𝗥𝗧𝗜𝗖𝗟𝗘  📱 Enhancing Emergency Department Patient Experience and Flow Through Real-Time Text-Messaging Updates https://nej.md/49K9hDX    𝗜𝗡𝗦𝗜𝗚𝗛𝗧𝗦 𝗥𝗘𝗣𝗢𝗥𝗧  ⚕️ The Search for Care Delivery Innovation https://nej.md/3VHV1Yv     𝗜𝗡𝗦𝗜𝗚𝗛𝗧𝗦 𝗜𝗡𝗧𝗘𝗥𝗩𝗜𝗘𝗪  💻 Coordination and Technology Drive Care Delivery Innovation https://nej.md/4cpT8pg     𝗙𝗥𝗢𝗠 𝗧𝗛𝗘 𝗘𝗗𝗜𝗧𝗢𝗥𝗦  🚑 Care Delivery Innovation in Action https://nej.md/43qzwgv    👉 Explore the current issue: https://nej.md/43mj7JX #HealthCare 

    • NEJM Catalyst Innovations in Care Delivery 
Vol. 5 No. 4 | April 2024
  • View organization page for NEJM Group

    89,899 followers

    Most of the 50% of Americans struggling with overweight or #obesity will start their weight loss journey with their primary care physician. The challenge to stay on top of advances in obesity management and treatment can be overwhelming. Management and Treatment of Obesity in Primary Care: An Evolving Landscape is a new CME program exploring the latest evidence on lifestyle, pharmacological, and surgical interventions, as well as recent progress in understanding the causes of obesity. Consisting of four distinct learning opportunities, each activity aims to equip primary care clinicians to navigate the complex, evolving landscape of obesity management. In this course you will learn and reinforce your understanding and skills of how to: 🔍 Examine the roles of environmental and genetic factors in obesity. 🧬 Articulate the mechanisms and pathophysiology of obesity. 📝 Review common risk factors and comorbidities associated with obesity. 📊 Assess multiple factors that influence the prevalence of obesity among diverse populations. 🩺 Evaluate the evolving landscape of nutrient-stimulated hormone-based treatment options for obesity, and management of common side effects of these medications for your clinical practice. 💡 Apply knowledge of current best practices in obesity management to confidently manage patients with obesity. Confidently manage patients with obesity. Learn more about this free CME program: https://nej.md/4crgXwz

    • Free CME Program
Management and Treatment of Obesity in Primary Care
Confidently manage patients with obesity.
Sign up today.
  • View organization page for NEJM Group

    89,899 followers

    Fragmentomics: The characteristics of a large number of DNA fragments. Fragmentomics involves the measurement and analysis of fragment lengths and the characteristics of the ends of the fragments (e.g., having a blunt or jagged end or having a specific sequence at the end, called an “end motif ”) and the patterns of the different lengths and fragment characteristics. There is a correlation between methylation and fragment end motif. DNA fragments from circulating tumor DNA, which can be in the blood of a person with cancer or precancer, are shorter, have more jagged ends, and have a different distribution of specific end motifs than the circulating free DNA in the blood from normal cells, which is present in the blood of all persons regardless of whether they have a tumor. Fragmentomics is also used in the study of cell-free DNA in the plasma of pregnant persons and transplant recipients.    To learn more about this NEJM Illustrated Glossary term, read “Cell-free DNA for Colorectal Cancer Screening” by Y.M. Dennis Lo, BM, BCh, DPhil, DM: https://nej.md/43noybx    Explore more terms: https://nej.md/glossary   

    • Visual representation of “fragmentomics”
  • View organization page for NEJM Group

    89,899 followers

    In a recent Case Record of the Massachusetts General Hospital, a 55-year-old man was evaluated at this hospital after a witnessed out-of-hospital cardiac arrest.    The patient had been eating at a restaurant late at night when he lost consciousness. A first responder used an automated external defibrillator to deliver a shock, and cardiopulmonary resuscitation (CPR) was initiated. Four minutes later, emergency medical services identified ventricular fibrillation, and defibrillation was performed. Intravenous amiodarone and epinephrine and intranasal naloxone were administered. Unstable ventricular tachycardia occurred, and the patient underwent cardioversion. He was transported to the emergency department of this hospital. The results of electrocardiography (ECG) performed before arrival at the hospital were suggestive of inferior ST-segment elevation myocardial infarction.    A review of systems could not be performed. The patient had no known medical history. He was not known to take any medications. He reportedly lived alone, worked in the service industry, and did not use tobacco or drink alcohol. His family history was unknown.    Read more about the case in “A 55-Year-Old Man with Cardiac Arrest, Cardiogenic Shock, and Hypoxemia,” which includes differential and final diagnoses from guest physicians based on evidence from the test results, by Robert Roswell,MD,FACP,FACC, et al., from Northwell Health, the Donald & Barbara Zucker School of Medicine, and elsewhere: https://nej.md/49NroJb  

    This content isn’t available here

    Access this content and more in the LinkedIn app

  • View organization page for NEJM Group

    89,899 followers

    Cerebral cavernous malformations (CCMs) are compact clusters of spongelike vascular spaces without intervening neural parenchyma that occur in the brain or spinal cord. At surgery, they appear as blebs or blood-filled bubbles, like a cluster of grapes, with a characteristic appearance on magnetic resonance imaging (MRI), as described below. CCMs are found in approximately 0.5% of the general population. In rare familial cases, the lesions also occur in the retina or skin. In the past, CCMs in the nervous system were called angiographically occult vascular malformations, because they typically cannot be detected on conventional angiography, and they have also been described as hemangiomas, cavernomas, and cavernous angiomas. Sporadic, single CCMs are most common, accounting for approximately 85% of cases; about 15% are familial, and CCMs induced by radiation are increasingly being identified. The prevalence of CCMs, coupled with increased detection with the widespread availability of cerebral imaging, suggests that many physicians will see patients with these lesions. Continue reading the Review Article “Cavernous Malformations of the Central Nervous System” by Edward Smith, M.D., from Boston Children's Hospital and Harvard Medical School: https://nej.md/49QMK8L 

    • Characteristic Features of CCMs on MRI Studies
  • View organization page for NEJM Group

    89,899 followers

    NEJM CareerCenter resource highlight: Unusual Parts of Compensation Packages When negotiating a job contract, don't limit yourself to the basics. Beyond salary and bonuses, consider unique perks that enhance your work satisfaction. From flexible schedules to tailored patient populations, physicians have successfully negotiated various unconventional requests. Understand your institution's flexibility, prioritize your needs, and articulate how each request contributes to efficiency and well-being. Remember, the key is not just asking, but justifying how it benefits both you and the organization. As the health care landscape evolves, out-of-the-box solutions are crucial for workforce sustainability. Don't be afraid to ask for what matters most to you – if you don't ask, you won't get it. Read more in “Unusual Parts of Compensation Packages” by Nisha Mehta, MD, a physician leader whose work focuses on physician empowerment, community building, and career longevity in medicine: https://lnkd.in/gbCKfPaD #PhysicianWellbeing

    This content isn’t available here

    Access this content and more in the LinkedIn app

Affiliated pages

Similar pages

Browse jobs

Funding

NEJM Group 1 total round

Last Round

Grant
See more info on crunchbase